Immunosuppression in renal transplantation and dyslipidemia, which factors should be considered?

Nephro-Urology Monthly

Volumn 5, Issue 5, 2013, Pages 1008-1009

  De Giorgi, Alfredo ^a   Fabbian, Fabio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Dyslipidemias; Immunosuppression; Kidney transplantation

Indexed keywords

CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STEROID; TACROLIMUS; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DYSLIPIDEMIA; GRAFT RECIPIENT; HEART GRAFT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LETTER; METABOLIC SYNDROME X; PRESCRIPTION; RISK FACTOR;

EID: 84894062707     PISSN: 22517006     EISSN: 22517014     Source Type: Journal    
DOI: 10.5812/numonthly.14189     Document Type: Letter

References (10)

1. Gaddi A, Cicero AF, Odoo FO, Poli AA, Paoletti R. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag. 2007;3(6):877-86.
2. Fabbian F, Bergami M, Molino C, De Giorgi A, Pala M, Longhini C, et al. Risk factors for metabolic syndrome in stable Italian renal transplant patients. Clin Exp Nephrol. 2011;15(4):560-6.
3. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. US Renal Data System 2012 Annual Data Report. Am J Kidney Dis. 2013;61(1 Suppl 1):e1-476.
4. Fabbian F, De Giorgi A, Pala M, Tiseo R, Manfredini R, Portaluppi F. Evidence-based statin prescription for cardiovascular protection in renal impairment. Clin Exp Nephrol. 2011;15(4):456-63.
5. Berg AL, Nilsson-Ehle P. ACTH lowers serum lipids in steroidtreated hyperlipemic patients with kidney disease. Kidney Int. 1996;50(2):538-42.
6. Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation. 1994;57(10):1479-83.
7. Deters M, Kirchner G, Koal T, Resch K, Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Dig Dis Sci. 2004;49(1):30-7.
8. Hosseini MS, Rostami Z, Einollahi B. Dyslipidemia after kidney trasplantation an correlation with Cylosporine level. Nephr Urol Mon. 2013;5(3):831-4.
9. Laufer G, Grablowitz V, Laczkovics A, Miholic J, Heinz G, Wollenek G, et al. The determinants of elevated total plasma cholesterol levels in cardiac transplant recipients administered low dose cyclosporine for immunosuppression. J Thorac Cardiovasc Surg. 1992;104(2):241-7.
10. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis. 1991;18(3):353-8.